Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Yasuchika Hasegawa

- PMLiVE

Takeda’s obesity drug Contrave launches in US

Clears cardiovascular safety hurdle to be third new weight-loss drug in recent months

- PMLiVE

Takeda appoints head of vaccines development

John Boslego will succeed Ralf Clemens

- PMLiVE

Takeda opens new UK office in High Wycombe

Hopes move to larger premises will help expand business

- PMLiVE

Takeda loses in lawsuit claiming cancer link to Actos

Ordered to compensate woman who claims drug gave her bladder cancer

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

- PMLiVE

Japan first to approve Roche’s lung cancer drug alectinib

Personalised medicine has same target as Pfizer’s Xalkori and Novartis’ Zykadia

Novartis building

Novartis charged in Japan over data falsification

Prosecutors claim pharma company employees manipulated Diovan data

- PMLiVE

Takeda drops prostate cancer drug in phase III

Suffers another late-stage pipeline blow as orteronel disappoints

- PMLiVE

Omontys terminal as Takeda switches off support

Japanese company ends anaemia treatment partnership with Affymax

EU flag

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links